

REFERENCES

- Ahmed N, Thorley R and Xia D et al.(1996):** Transgenic mice expressing rabbit C-reactive protein exhibit diminished chemotactic factor-induced alveolitis. *Am J Respir Crit Care Med*; 153: 1141-7.
- Allair AD, Ballenge KA and Wells SR.(2000):** Placental apoptosis in preeclampsia. *Obstet Gynecol*; 96: 271.
- American College of Obstetricians and Gynecologists Committee on Obstetric Practice (2002):** Diagnosis and management of preeclampsia. *Int J Gynecol Obstet*; 77: 67-75 (ACOG Practice Bulletin).
- Aquilma J, Barnett A and Thompson, O et al.(1999):** Second trimester maternal serum inhibin. A concentration as an early marker for preeclampsia. *Am J Obstet Gynecol*; 181: 131.
- Arias F (1993):** Prolonged pregnancy. In: *Practical Guide to High-Risk Pregnancy and Delivery*. 2nd ed. Mosby Yearbook Inc. St. Louis, Baltimore, Boston; 150-161.
- Askie LM, Duley L, Henderson-Smart DJ, Stewart LA (2007):** Paris Collaborative Group. Antiplatelet agents prevention for preeclampsia: a meta-analysis of individual patient data. *Lancet*; 369:1791–8.
- Bainbridge SA, Sidle, EH and Smith GN et al.(2005):** Direct placental effect of cigarette smoking protect women from preeclampsia in the specific roles of carbon monoxide and antioxidant systems in the placenta. *Med Hypotheses*; 64: 17.
- Ballou SP and Kushner I(1992):** C-reactive protein and the acute phase response. *Adv Intern Med* 37: 313.

- Bardeguez AD, McNerney R, Frieri M, Verma UL, and Tejani N(1991):** Cellular immunity in preeclampsia: alterations in T lymphocyte subpopulations during early pregnancy. *Obstet Gynecol*; 77: 859-62.
- Batashki L, Milchev N and Topalovska D et al.,(2006):** C-reactive protein in women with preeclampsia. *Akush Ginekol (Sofia)*; 45(Suppl. 1): 47-50.
- Belfort MA, Saade GR, Grunewald C, Dildy GA, Abedejos P and Herd JA, Nisell H(1999):** Associates of cerebral perfusion pressure **with** headache in women with preeclampsia. *Br J Obstet Gynaecol*; 106(8): 814-21.
- Bhakdi S., Torzewski M., Klouche M. and Hemmes M. (1999):** Complement and atherogenesis: Binding of CRP to degraded, nonoxidized LDL enhances complement activation. *Arterioscler Thromb Vasc Biol*; 19: 2348-2354.
- Blackburn CA, Keelan JA and Taylor RS et al.(2004):** Two-stage elevation of cell free fetal DNA in maternal sera before onset of preeclampsia. *Am J Obstet Gynecol*; 190: 707.
- Bolte AC, Van Geijn HP, Dekker GA(2001):** Management and monitoring of severe preeclampsia. *Eur J Obstet Gynecol Reprod Biol*; 96(1): 8.
- Borghi C, Esposti DD, Immordino V, et al.(2000):** Relationship of systemic haemodynamics, left ventricular structure and function, and plasma natriuretic peptide concentration during pregnancy complicated by preeclampsia. *Am J Obstet Gynecol*; 183: 140.
- Bosio PM, Wheeler T and Anthong F et al.(2001):** Maternal plasma vascular endothelial growth factor concentration in normal and hypertensive pregnancies. *Am J Obstet Gynecol*; 174: 146.

- Braekke K, Holthe MR, Harsem NK et al.,(2005):** Calprotectin, a marker of inflammation, is elevated in maternal but not in the fetal circulation in preeclampsia. *Am J Obstet Gynecol* ;193(1):227-33.
- Brosnan M J (2008).** One step beyond: glutathione peroxidase and endothelial dysfunction. *Hypertension*; 51:825–6.
- Brown CEL, Purdy PD and Cunningham FG (1988):** Head computed tomographic scans in women with eclampsia. *Am J Obstet Gynecol* 159: 915.
- Brown DW, Dueker N, Jamieson DJ et al.,(2006):** Preeclampsia and the risk of ischemia stroke among young women. Results from the stroke. Prevention in young women study. *Ther Adv Cardiovasc Dis* ; 2:249-59.
- Buchbinder A, Sibai BM, Caritis S et al.,(2002):** Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. *Am J Obstet Gynecol*; 186: 66.
- Cermak J, Key NS and Bach RR et al.,(1993):** C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. *Blood*; 82: 513-20.
- Chappell L and Bewley S (1998):** Preeclamptic toxemia: The role of uterine artery Doppler. *Br J Obstet Gynaecol*; 105: 379.
- Chappell LC, Seed PT, Briley A et al.,(2002):** A longitudinal study of biochemical variables in women at risk of preeclampsia. *Am J Obstet Gynecol*; 187: 127.
- Chavarria ME, Lara-Gonzalez, Gleason A et al.,(2003):** Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. *Am J Obstet Gynecol*; 188: 986.

- Chipchuse J, Peebles D and Rodeck C (2003):** Severe preeclampsia and cerebral blood volume response to postural change. *Obstet Gynecol*; 101: 86-92.
- Cnossen JS, Ter Riet G, Mol BW et al.,(2009).** Are tests for predicting pre-eclampsia good enough to make screening viable?A review of reviews and critical appraisal. *Acta Obstet Gynecol Scand* ;88: 758–65.
- Conde-agudelu A, Belizan JM (2004):** Risk factor for pre-eclampsia in a large cohort of Latin American and Caribbean women. *Br J Obstetric Gynaecol*; 107: 75.
- Creasy RK, Resnick R, Iams JD et al.,(2004):** *Maternal-Fetal Medicine: Principles and Practice*. 5th ed. Philadelphia: WB Saunders.
- Cunningham F, Gant NF, Leveno KJ et al.,(2001):** Hypertensive disorders in pregnancy , in *Williams Obstetrics*; 21st edition, Elsevier; P: 567.
- Cunningham F, Kenneth J, Steven LB et al.,(2005):** Hypertensive disorder in pregnancy, in *Williams Obstetric*, 22nd edition, Elsevier; P: 764.
- Cunningham F and Lindheimer M (1992):** Hypertension in pregnancy. *New England Journal of Medicine*; 236: 927.
- Cunningham G, Gant NF and Leveno KJ et al.(2001):** Hypertensive disorder in pregnancy, common complication of pregnancy. In: Andrea S, Susen R, Noujaim and Karen D (eds): *Williams Obstetrics* 21st edition McGraw-Hill; 568-618.
- Dekker G and Sibai B (2001):** Primary, secondary and tertiary prevention of preeclampsia-*Lancet*; 357: 209-215.

- Delia M.Paternoster, Sara Fantinato, Andrea stella et al.,(2008):** C-reactive protein in hypertensive disorder in pregnancy. *BMJ* ;335:1059.
- Deveci K, Sogut E, Evliyaoglu O, Duras N (2009).** Pregnancyassociated plasma protein-A and C-reactive protein levels in pre-eclamptic and normotensive pregnant women at third trimester. *J Obstet Gynaecol Res*; 35: 94–98.
- Dowling PC and Cook SD (1972):** Immune events in demyelinating disease. In Wolfgang F., Ellism GW (eds): *Multiple sclerosis*. Academic Press Inc. New York, 269-277.
- DRG CRP, HS (2005):** High sensitivity enzyme immunoassay for the quantitative determination of C- reactive protein concentration in human serum. DRG International; 1: 11: 11-11.
- Duckitt K and Harrington D (2005):** Risk factors of preeclampsia at antenatal booking: Systemic review of controlled studies, *BMJ*; 330:565.
- Eklom E (1997):** Hemodynamic measures in prediction of preeclampsia: *Acta Obstet Gyencol Scand*; 164(76): 101.
- Ernest E, Hammerschmidt DE, Bagge U, Matria A, Dormandy JA (2000):** Leukocytes and the risk of ischemic diseases. *JAMA*; 257 (17): 2318.
- Estelles A, Gilabert J Grancha S et al.,(1998):** Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in sever preeclampsia. *Thromb Haemost* ; 79: 5000.
- Ferris TR (1988):** Prostanoids in normal and hypertensive pregnancy. *Handbook of hypertension*. In: Rubin PC (editor). Amsterdam: Elsevier ; 10: 102.

- Festa A, D'Agostino R Jr, Howard G et al.,(2000):** Chronic sub clinical inflammation as part of the insulin Resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). *Circulation*; 183: 853.
- Friedman SA, Lindheimer MD (1999):** prediction and differential diagnosis. In: Lindheimer MD. Roberts JM, Cunningham FG eds); Shesley's hypertensive disorders in pregnancy 2nd ed. Stm-Ford CT. Appleton and Lange; P: 201.
- Friedman SA, Schiff E, Kao L, Sibai BM (1995):** Neonatal outcome after preterm delivery of preeclampsia, *Am J Obstet Gynecol* ; 172: 1785-8.
- Gaunt G and Ramin K (2001):** Immunological tolerance of the human fetus. *Am J Perinatol*; 18(6): 299.
- Garcia RG, Celed.n J, Sierra-Laguado J, Alarc.n MA, Luengas C, Silva F, et al., (2007):** Raised C-reactive protein and impaired flow-mediated vasodilation precede the development of preeclampsia. *Am J Hypertension*; 20(1): 98-103.
- Garvic VO (2000):** Hypertension in pregnancy: Diagnosis and treatment. *Mayo Clin Proc*; 75 1071-1076 (Level III).
- Gervasi MT, Chaiworapongsa T, Pacora P, Naccasha N, Yoon BH, Maymon E and Romero R (2001):** Phentotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. *Am J Obstet Gynecol*; 185: 792-7.
- Granger, JP, Alexander, BT, Benett WA, Khaht RA (2001):** Pathophysiology of pregnancy-included hypertension. *Am J Hypertension*; 14: 1785.
- Greer A (1994):** Haemostasis and thrombosis in pregnancy in: Haemostasis and thrombosis in obstetrics and Gyencology. Bloom Al, Forbes CD, Thomas DP, Tuddenham EGD (eds.), 3rd edition, Edinburgh Churchill Livingstone; 987-993.

- Grunewald C (1997):** Biochemical prediction of preeclampsia: Acta Obstet Gyencol Scand; 164: 76.
- Guven MA, Coskun A, Ertas IE, Aral M, Zencirci B, Oksuz H (2009).** Association of maternal serum CRP, IL-6, TNF-alpha, homocysteine, folic acid and vitamin B12 levels with the severity of preeclampsia and fetal birth weight. *Hypertension with Pregnancy*; 28: 190–200.
- Hadded B, Desuau D and Jeffrey C et al.,(2001):** Serum B2-micoglobulin level as an early marker of preeclampsia. Am J Obstet Gyencol; 182: 595.
- Halligan A, Bonnar J, Shappard B, et al.,(1994):** Haemostatic, Fibrinolytic, and endothelia variables in normal pregnancies and preeclampsia. Br J Obstet Gyencol; 101: 488.
- Harlow FH, Brown MA, Brighon TA, et al.,(2002):** Platelet activation in the hypertensive disorder of pregnancy. Am J Obstet Gyencol; 187: 688.
- Hayashi M, Hamada Y, and Ohkura T (2004):** Elevation of granulocyte macrophage colony stimulating factor in the placenta and blood in preeclampsia. Am J Obstet Gynecol; 190: 456.
- Heikkinen J, Mottonen M, Komi J, Alanen A and Lassila O (2003):** Phenotypic characterization of human decidual macrophages. Clin Exp Immunol; 131: 498-505.
- Hilary S,Robert W,Rebecca G,Peter J et al.,(2010):** does c-reactive protein predict recurrent preeclampsia. Hypertention in pregnancy ;29:399-409.
- Hind CR and Pepys MB (1984):** The role of serum CRP measurement in clinical practice. Int Med; 5: 112-151.

- Hiroko M (1998):** Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. *J Clin Endocrin Metab*; 83(9): 3225-3229.
- Holzgrevé W, Steinbor CL and Kulz T et al.,(2001):** Elevation in erythroblast count in maternal blood before the onset of preeclampsia. *Am J Obstet gynecol*; 184: 165.
- Hu X, Ye R and Yang Z (1999):** The clinical study on urinary albumin and calcium output in 24 hours to serve as early markers for pregnancy induced hypertension *Zhonghua. Fu Chann Ke Zu Zhi*; 34(12): 709-711.
- Hubel CA, Powers RW, Snaedal S, Gammill HS, Ness RB, Roberts JM, et al.,(2008).** C-reactive protein is elevated 30 years after eclamptic pregnancy. *Hypertension*; 51(6):1499–1505.
- Hvilsom GB, Thorsen P, Jeune B and Bakketeig LS (2002):** C-reactive protein: Aserological marker for preterm delivery. *Acta Obstet Gyencol Scand*; 81: 424-429.
- Hwang HS, Kwon JY, Kim MA, Park YW, Kim YH (2007):** Maternal serum highly sensitive C-reactive protein in normal pregnancy and pre-eclampsia. *Int J Gynaecol Obstet*; 98: 105-109.
- Jackson DW, Sciscione A and Hartly TL et al.,(1996):** Lysosomal enzymuria in preeclampsia. *Am J kidney Dis*; 27(6): 826-833.
- Janeway CA, Travers P and Walport M et al.,(2001):** Immunobiology: the immunosystem in health and disease. New York. NY: Garland Publishing; 21-52.
- Jaye DL and Waits KB (1997):** Clinical applications of C-reactive protein in pediatrics. *Pediatr infect Dis J*; 16: 735.

- Jialal T, Devaraj S and Venugopal SK (2004):** CRP: risk marker or mediator in atherothrombosis. *Hypertension*; 44: 6-11.
- John JH, Ziebland S, Yudkin P et al.,(2002):** Effects of fruit and vegetable consumption on plasma antioxidant concentration and blood pressure: A randomized controlled trial. *Lancet*; 359: 1969-74.
- Jupe D (1996):** the acute phase response and Laboratory testing. *Aust Fam Phys*; 25: 324.
- Katz VL, Richard T and Moodle J (2000):** Preeclampsia into eclampsia: Toward a new paradigm. *J Obstet Gyencol*; 182: 1389.
- Karinen L, Leinonen M, Bloigu A et al.,(2008).**Maternal serum Chlamydia pneumoniae antibodies and CRP levels in women with preeclampsia & gestational hypertension. *Hypertension with Pregnancy*;27:143-58.
- Keelan JA, Taylor R, Schellenberg JC et al.,(2002):** Serum activin A. Inhibin A, and Folistatin conentation in preeclampsia of small for gestational age pregnancies. *Obstet Gyencol*; 99: 267.
- Khedun SM, Naicker T and Moddley J (2000):** Tissue Kallikreis activity in pregnancy. *Aust NZJ Obstet Gyencol*; 40(4): 451.
- Kluft C and de Maat MP (2002):** Sensitive markers of inflammation make it possible to study the chronic process: The rise of interest in low levels of C-reactive protein. *Vasc Pharmacol*; 39: 99-104.
- Kumru S, Aydin S, Gursu MF, Ozacan Z (2004):** Changes of serum paraoxonase (an HDL-cholesterol-associated Lipophilic antioxidant) and arylesterase activities in sever preeclamptic women. *Eur J Obstet Gyencol Reprod Bio*; 2: 177-81.
- Kumru S, Godekmerdan A, Kutlu S and Ozcan Z (2006):** correlation of maternal serum hs c-reactive protein levels with biochemical and clinical

parameters in preeclampsia. Eur J Obstet Gynecol and Reprod Biol; 124(2): 164-167.

Kushner I, Jiang SL, Zhang D et al., (1995): Do post-transcriptional mechanisms participate in induction of CRP by IL-6,IL1. Ann N Y Acad Sci;762: 102.

Lees C, Parra M, Missfelder-Lobos H et al., (2001): Individualized risk assessment for adverse pregnancy outcome by uterine artery Doppler at 23 weeks. Obstet Gyencol; 98(3): 369.

Levine KJ, Qian C and Leshane ES et al., (2004): Two stage elevation of cell free fetal DNA in maternal sera before onset of preeclampsia.Am J Obstet Gynecol 190: 707.

Li YH, Chen JH and Tsai WC et al., (2002): Synergistic effect of thrombodulin promoter-33 G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Hemost; 87(1): 86.

Livingstone JC, Chin R, Haddad B et al., (2000): Reduction of vascular endothelial growth factor and placental growth factor concentration in sever preeclampsia. Am J Obstet Gyencol; 183: 554.

Lorentzon B, Endreson MJ and Clausen T et al., (1994): Fasting serum free fatty acids and triglycerides are increased before 20 weeks of gestation in women who later develop preeclampsia. Hypertension in pregnancy; 103: 74-79.

Lusis AJ (2000): Atherosclerosis. Nature; 407(6801): 233-241.

Ma S, Bai S and Bian X (1999): Study on thrombomodulin and plasminogen activator inhibitor type-1 in Patients of pregnancy induced hypertension. Zhongua Fu Chan Ke Za Zhi; 34(12): 712.

- Malee MP, Make KM and Azuma SD et al., (1992):** Increase in plasma atrial natriuretic peptide concentration antedate clinical evidence of patient preeclampsia, *J Clinical Endocrinol*; 133: 1266.
- Manten GT, Vander Hoek YY, Marko Sikkema J, Voorbig HA, Hameeteman TM, Visser GH, and Franx A (2005):** The role of lipoprotein (a) in complicated by preeclampsia. *Med Hypothesis*; 64: 162-9.
- Matter F and Sibai BM (2000):** Eclampsia: Risk factor for maternal morbidity. *J Obstet Gyencol*; 182: 307.
- Menha Swellam, Nervana Samy, Susan Abdel Wahab and Mohamed Saeed Ibrahim (2009):** Emerging role of endothelial and inflammatory markers in preeclampsia. *Disease Markers*; 26 :127–133.
- McCall (1953):** Cerebral circulation and metabolism in toxemia of pregnancy: observations on the effects of veratrum viride and a presolin (1-hydrazinophthalazine). *Am J Obstet Gynecol*; 66: 1015-1030. Quoted from: David K James, Philip J Steer, Carl PW Weiner, and Benard Gonik, hypertension in high risk pregnancy: management options 3rd ed., USA, El Sevier; p. 772-797.
- McKeeman GC, Aradill JE, Goldwell, CM et al., (2004):** Soluble vascular endothelial growth factor receptor: (SFIT-1) is increased throughout gestation in patients who have preeclampsia developed *Am J Obstet Gyencol*; 191: 1240.
- Mei S, Gu H, Wang Q, Zhang S, Zeng Y (2008).** Preeclampsia outcomes in different hemodynamic models. *J Obstet Gynaecol Res*; 34: 179–188.
- Melchiorre K, Wormald B, Leslie K, Bhide A, Thilaganathan B (2008):** First-trimester uterine artery Doppler indices in term and pre-term preeclampsia. *Ultrasound Obstet Gynecol*; 32: 133–7.

- Millar TGB, Carpell SK and Albano JDM (1996):** Early prediction of preeclampsia by measurement of kallikrein and creatinine on a random urine sample. *Br J Obstet Gynaecol*; 103: 421-426.
- Mirzaie F, Rahimi F and Hossain A (2009):** Association of maternal c-reactive protein levels with severity of preeclampsia. *Acta Medica Iranica*;47,4:295.
- Mistry HD, Wilson V, Ramsay MM, Symonds ME, Broughton Pipkin F (2008):** Reduced selenium concentrations and glutathione peroxidase activity in preeclamptic pregnancies. *Hypertension* ;52:881–8.
- Moran P, Lindheimer MD, Davison, JM (2004):** The renal response to preeclampsia. *Semin Nephrol*; 24: 588.
- Moretti M, Phillips M, Abouzeid A et al., (2004):** increased breath markers of Oxidative stress in normal pregnancy and in preeclampsia. *Am J Obstet Gyencol*; 190: 1184.
- Moseman CP and Shelton S (2002):** Permanent blindness as a complication of pregnancy induced hypertension. *Obstet Gynecol*;100 :943.
- National High Blood Pressure Education Program Working Group On high Blood Pressure in Pregnancy (2000):** Report of The National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. *Am J Obstet Gynecol*; 1832: S1-S22.
- Nishikawa S, Miyamoto A, Yamamoto H et al., (2001):** Preeclamptic serum enhances endothelial converting enzyme expression in cultured endothelial cell. *Am J hypertens*; 14(1): 77.
- Noris M, Todeschini M, Cassis P et al., (2004):** L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species hypertension; 43: 614.

- Odegand RA, Vatten LJ and Nilsen et al., (2000):** Preeclampsia with fetal growth
Obstet Gyencol; 96: 950.
- Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, et al., (2004).**Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med; 351(25):2599–2610.
- Papageorghiou AT (2008).** Predicting and preventing preeclampsia where to next? Ultrasound Obstet Gynecol; 31:367–70.
- Pasceria V, Willerson JT, Yeh ET (2000):** Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation; 102: 2165-8.
- Pearson TA, Mensah GA and Alexander RW et al., (2003):** Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for health care professionals from the centers for disease control and prevention and the American Health Association Circulation; 107: 499-511.
- Petroff MG, Sedlmayr P, Azzola D and Hunt JS (2002):** Desidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. J Reprod Immunol 56: 3-17.
- Phocas I, Rizos D and Papoulias J et al., (2001):** A comparative study of serum soluble vascular cell adhesion molecule-1 and soluble intercellular adhesion molecule-1 in preeclampsia. J Perinatal; 20(2): 114.
- Picklesimer AH, Jared HL, Moss K, Offenbacher S, Beck JD, Boggess KA (2008):** Racial differences in C-reactive protein levels during normal pregnancy. *Am J Obstet Gynecol*; 199: 523.
- Powers RW, Dunbar MS and Gallaher MJ et al., (2003):** The 677 CT methylene tetrahydrofolate reductase mutation pregnancy. Obstet Gyencol; 101: 762.

- Rebello I, Carvalho-Guerra F, Pereira-Leite L and Quintanilha A (1995):** Lactoferrin as a sensitive blood marker of neutrophil activation in normal pregnancy. Eur J Obstet Gynecol Reprod ; 14: 2386-2391.
- Redman CW and Sargent IL (2003):** Preeclampsia, the placenta, and the maternal systemic inflammatory response: a review. Placenta; 24: 521-527.
- Redman CW (2000):** Preeclampsia the year book of obstetrics and gynecology, 8th edition; P: 97.
- Rentnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B(2003):** C-reactive protein and Gestational diabetes: The central role of maternal obesity. J Clin Endocr Metab; 88: 3507-12.
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP and Hennekens CH (1998):** Plasma concentration of C-reactive protein and the risk of developing peripheral vascular disease. Circulation; 97: 425-428.
- Ridker PM, Glynn RJ, Hennekens CH (1998):** C-reactive protein adds to the predictive value of total and HD2 cholesterol in determining risk of first myocardial infarction. Circulation; 97: 2007.
- Ridker PM (2001):** High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation; 103(13): 1813.
- Robert JM (1994):** Pregnancy related hypertension in maternal-fetal medicine, principles and practice, endn. WB Saunders Co.
- Robert JM and Cooper DW (2001):** Pathogenesis and genetic of preeclampsia: Lancet; 357: 53-56.

- Rodriguez MH, Masaki DI and Mestman J et al., (1988):** Calcium/Creatinine ratio and Microalbuminuria in the prediction of preeclampsia. Am J Obstet Gynecol; 159: 1452.
- Ross R (1999):** Atherosclerosis an Inflammatory disease. N Eng L J Med; 340(2): 115.
- Sacks GP, Syeani L, Lavery S, Trew G (2004):** Maternal C-reactive protein levels are raised at 4 weeks gestational. Hum Reprod; 19: 1025-30.
- Saijo Y, Maeda K and Nakaya Y et al., (2001):** Altered sensitivity to a novel vasoconstrictor endothelin-1 (1-31) in myometrium and umbilical artery of women with severe preeclampsia. Biochem Biophys Res Commun; 286(5): 989.
- Saito M, Ishimitsu T, Minami J, Ono H, Ohru M, Matsuoka H(2003):** Relation of plasma high-sensitivity C-reactive protein to traditional Cardiovascular risk factor Atherosclerosis; 1: 73-9.
- Saito S, Shiozaki A, Nakashima A, Sakai M and Sasaki Y (2007):** The role of immune system in preeclampsia. Molecular aspects of medicine, 28;2:192-209.
- Sargent IL (1993):** Maternal and fetal immune responses during pregnancy. Exp Clin Immunoglobulins; 10: 85.
- Sattar N, Ramsay J, Crawford L, Cheyne H, Greer IA (2003):** Classic and novel risk factor parameters in women with a history of preeclampsia. Hypertension; 42(1):39–42.
- Savvidou MD, Lecs CC and Parra M et al., (2002):** Levels of C-reactive protein in pregnant women who subsequently develop preeclampsia. Br J Obstet Gynaecol; 109(3): 297-301.

- Serin YS, Ozcelik B and Bapbuo M et al., (2002):** Predictive value of Tumour Necrosis factor alpha (TNF-alpha) in preeclampsia. Eur J Obstet Gynecol Biol; 100(2): 143.
- Shaarawy M and Abdel-Magid MA (2000):** Plasma endothelin-1 and mean arterial pressure in prediction of preeclampsia. Int J Gyencol Obstet; 68: 105.
- Sheehan HL (1950):** Pathological lesion in the hypertensive toxemias of pregnancy. In: Hammond J, Browene FJ, Wolstenholem GEW (eds): Toxemias of pregnancy, human and veterinary. Philadelphia J Steer, Carl P Weiner, and Bernard Gonik. Hypertension in high risk pregnancy: management options, 3rd ed, USA, El Sevier, p 772-797.
- Shipp TD and Wilkine HL (1997):** The association of early onset fetal growth restriction, elevated maternal alpha fetoprotein in preeclampsia. Prenatal Diagnosis; 17: 303.
- Schultz DR and Arnold PI (1990):** Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1 acid glycoprotein and fibrinogen. Semin Arthritis; 29, 3: 129-147.
- Sibai BM (1982):** Hypertension in pregnancy. Clin Obstet Gynecol; 35: 315.
- Sibai BM (1988):** Pitfalls. In: diagnosis and management of preeclampsia. Am J Obstet Gyencol; 159: 1.
- Sibai BM (1995):** Hypertension in pregnancy and respiratory system. Clin Obstet Gyencol; 32: 315.
- Sibai BM (1996):** Treatment of hypertension in pregnant women. N Engl J Med; 335: 257.

- Sibai BM (2003):** Diagnosis and management of gestational Hypertension and preeclampsia. *Obstet Gyencol*; 102: 181.
- Sibai BM (2004):** Magnesium sulphate prophylaxis in preeclampsia: Lessons learned from recent trials. *Am J Obstet Gynecol*; 190: 1520.
- Silver RK, Turbo JM, Baried JA et al.,(1990):** Soluble factors produced by isolated 1st trimester chorionic villi directly inhibit the immune system. *Am J Obstet and Gyencol*; 163: 84.
- Smith GN, Walker MC, Liu A et al.,(2009).** A history of preeclampsia identifies women who have underlying cardiovascular risk factors. *Am J Obstet Gynecol*; 200(1):58.e1–58.e8.
- Stamilio DM, Sehder HM, Morgan MA et al.(2000):** Can antenatal clinical and biochemical markers predict the development of sever preeclampsia? *Am J Obstet Gyencol*; 182: 589.
- Stubbs TM, Lazarchick J, van Porsten JP et al.,(1986):** Evidence of accelerated platelet production and consumption in nonthrombocytopenic preeclampsia. *Am J Obstet Gyencol*; 155: 263.
- Stuveling EM, Bakker SJ, Hillege HL et al.,(2004):** C-reactive protein modifies the relationship between blood pressure and microalbuminuria. *Hypertension*; 4: 791-6.
- Stuveling EM, Hiillege HL, Bakker SJ et al.,(2003):** C-reactive protein is associated with renal function abnormalities in a nondiabetic population. *Kidney Int*; 2: 654-61.
- Teren E, Escudero C and Moya W et al.(2001):** Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with preeclampsia. *Int J Gyencol Obstet*; 5: 243-249.

- Thompson D, Pepys MB and Wood SP (1999):** Physiological structure of human c-reactive protein. *Structure*; 7: 169-177.
- Tinnakorn Chaiworapongsa, Roberto Romero, Jimmy Espinoza et al.,(2004):** Evidence supporting a role for blocked of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. *A J of Obstet and Gynecology*; 190: 1541-50.
- Tjoa ML , van Vugt JM , Blankenstein MA et al., (2003):** Elevated C-reactive protein levels during first trimester of pregnancy are indicative of preeclampsia and intrauterine growth restriction. *J Report Immunol*; 59: 29-37.
- Ustun Y, Engin-Ustun Y and Komaci M (2005):** Association of fibrinogen and C-reactive protein with Severity of preeclampsia. *Eur J Obstet Gyencol Reprod Biol*; 121(2): 154-8.
- Walf M and Thadhani R (2003):** First trimester C-reactive protein and subsequent gestational diabetes. *Diabetes Car*; 26: 819-824.
- Walf M , Kettyl E , Sandler L et al.,(2001):** Obesity and preeclampsia: The potential role of inflammation. *Obstet Gyencol*; 98: 7857-762.
- Walker JJ (1998):** Advances in the management of sever preeclampsia and antihypertensive therapy. In: Bonnar J (ed): *Recent Advances in Obstetrics and Gynecology*. London, Churchill Livingstone; 3: 805-815.
- Walsh SC (1994):** Lipid peroxidation in pregnancy. *Hypertens Preg*; 13: 1.
- Wilson BJ, Watson MS, Prescott GJ et al.,(2003):** Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from Cohort Study. *BMJ*; 326: 845.

- Witlin AG, Sibai BM (1999):** Diagnosis and management of women with haemolysis elevated Liver enzymes and low platelets count (HELLP) syndrome. Hosp Physician; 40: 49.
- Wang Z and Zhu Y (2001):** The role of placental isoferitin as a predictive value of preeclampsia. Zhonghua Fu Chan Ke; 36: 209.
- Yoneyama Y, Suzuki S, Sawa R et al.,(2002):** Relation between adenosine and T-helper 1/T helper 2 imbalance in women with preeclampsia. Obstet Gynecol; 99: 641-6.
- Yoon BH, Jun JK, Park KH et al.,(1996):** Serum C-reactive protein, white blood cell count, and amniotic fluid white blood cell count in women with preterm premature rupture of membranes. Obstet Gyencol; 88: 1034-1040.
- Young B, Glesson M, Cripps AW (1991):** C reactive protein: A critical review. Pathology ; 23: 118.
- Yudkin JS, Stehouwer CD, Emeis JJ et al.,(1999):** C-reactive protein in healthy subjects: Association with obesity, Insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol ; 19: 972-8.
- Yusuf U, Yaparak E, Mansur K (2004):** Association of fibrinogen and C-reactive protein with severity of preeclampsia Eur J Obstet Gyencol; 121: 154-158.
- Zeeman BG, Hatab, Twikler DM (2004):** Increased large vessel cerebral blood flow in severe preeclampsia by magnetic resonance (MR) evaluation presented at the 24th annual Meeting of the society for maternal fetal medicine, New Orleans, LA, February 2.

Zhang J, Meikie S and Trumble A (2003): Severe maternal morbidity associated with hypertensive disorder in pregnancy in The United States. Hypertension with pregnancy; 2: 203.

Zhong XY, laivuori H , Livingston JC et al.,(2001): Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentration in the plasma of pregnant women with preeclampsia. Am J Obstet Gyencol; 184: 414.

Zwaka TP, Hombach V and Torzewski J (2001): C-reactive protein mediated low density lipoprotein uptake by macrophages. Circulation 103, 1194-1197.